C12N 2770/36134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2770/36134 (Use of virus or viral component as vaccine) appears on 186 US grants and 285 published applications in this corpus.
Search patents in C12N- Granted patents
- 186
- Published applications
- 285
- Assignees
- 134
- Inventors
- 385
- Latest grant
- 16 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1999 | 2 | 0 |
| 2000 | 0 | 0 |
| 2001 | 2 | 0 |
| 2002 | 0 | 1 |
| 2003 | 5 | 4 |
| 2004 | 1 | 4 |
| 2005 | 0 | 4 |
| 2006 | 1 | 3 |
| 2007 | 2 | 8 |
| 2008 | 1 | 4 |
| 2009 | 1 | 4 |
| 2010 | 5 | 7 |
| 2011 | 1 | 10 |
| 2012 | 3 | 3 |
| 2013 | 8 | 10 |
| 2014 | 7 | 16 |
| 2015 | 9 | 11 |
| 2016 | 13 | 13 |
| 2017 | 11 | 13 |
| 2018 | 8 | 9 |
| 2019 | 12 | 22 |
| 2020 | 12 | 16 |
| 2021 | 13 | 20 |
| 2022 | 15 | 33 |
| 2023 | 22 | 23 |
| 2024 | 15 | 18 |
| 2025 | 10 | 18 |
| 2026 | 7 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Alphavirus neoantigen vectors and interferon inhibitors16 Jun 2026US 12,653,883 B2Seattle Project Corp.
- Human monoclonal antibodies to Venezuelan equine encephalitis virus and uses therefor2 Jun 2026US 12,642,847 B2Vanderbilt University
- Galectin-targeting immunotherapy26 May 2026US 12,636,341 B2VLP Therapeutics, LLC
- Chikungunya vaccine formulations21 Apr 2026US 12,605,436 B2Valneva SE
- Single shot Chikungunya virus vaccine21 Apr 2026US 12,605,437 B2Valneva SE
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
- Dna vaccine for fish against salmonid alphavirus27 Aug 2026US 2026/0248901 A1Intervet Inc.
- Treatment of atopic dermatitis using self-replicating rna expressing il-3120 Aug 2026US 2026/0240967 A1Ceva Sante Animale
- Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp320 Aug 2026US 2026/0240977 A1Valneva SE
- Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases6 Aug 2026US 2026/0224687 A1Centre National De La Recherche Scientifique
Most cited
By later US patents
- Zika virus RNA vaccines108US 10,124,055 B2ModernaTX, Inc. · 2018
- Zika RNA vaccines85US 10,449,244 B2ModernaTX, Inc. · 2019
- Antigen library immunization76US 6,541,011 B2Maxygen, Inc. · 2003
- Strain of the western equine encephalitis virus67US 6,800,289 B2Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence · 2004
- Animal protein free media for cultivation of cells33US 7,955,833 B2Baxter Healthcare S. A. · 2011